Clinical Trial Detail

NCT ID NCT02323113
Title Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Millennium Pharmaceuticals, Inc.
Indications

acute myeloid leukemia

Therapies

Mivavotinib

Age Groups: adult

No variant requirements are available.